On February 14, 2013, The American Academy of Pediatrics has recognized neurofeedback as being as effective as medication for attention deficit hyperactivity disorder.
Enough evidence has been produced for the American Academy of Pediatrics to acknowledge neurofeedback’s efficacy in children exhibiting symptoms of AD/HD that it has now become as recognized as medication on the chart of Psychosocial Interventions.
But does that mean your insurance company will reimburse you for your treatments at Asheville Brain Training? Probably not.
That’s because it takes insurance companies a loooong time to catch up to the research, amend their policies, and — ultimately — hand over the cash.
And with all the changes and uncertainty that may or may not befall the insurance industry in the coming years, it’s a safe bet to assume that your neurofeedback treatment will NOT be reimbursed.
View the chart of Child and Adolescent Psychosocial Interactions: 2-AmericanAcademyChartofPedCRPsychosocialInterventions
Read the study published by the ISNR for evidence backing biofeedback as suggesting a change to a LEVEL 1 reimbursable healthcare service to treat Attention Deficit Hyperactivity Disorder.
Read more about the ISNR, International Society for Neurofeedback and Research, a non-profit organization dedicated to researching better brain health through neurofeedback.
This post was edited and updated on January 15th, 2017/